Preclinical studies of group A Streptococcal vaccine candidates (2010–2012)

Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Grant type:
NHMRC Development Grant
  • Professor
    School of Chemistry and Molecular Biosciences
    Faculty of Science
    Affiliate Professor
    Institute for Molecular Bioscience
Funded by:
National Health and Medical Research Council